- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
FDA granted Breakthrough Therapy Designation to MindMed's MM120 for treating Generalized Anxiety Disorder and Major Depressive Disorder.
4 reports, 4 independent
Updated Sep 2
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Breakthrough Therapy Designation to MindMed's MM120 for treating Generalized Anxiety Disorder and Major Depressive Disorder.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyMind Medicine (MindMed) Inc. (MNMD)’s MM120 Earns FDA Breakthrough Status in Anxiety Treatment We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Mind Medicine (MindMed)
- Motley FoolIf You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today Mind Medicine stock is a speculative play on future potential for psychedelics as therapeutic trea
- Business WireMindMed Reports Q2 2025 Financial Results and Business Updates --Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (G
- GuruFocus.comMind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full